Health minister Mark Butler said reimbursed access to PAXLOVID will include the around 160,000 people between 60-69 years of age with mild to moderate COVID-19 with one additional risk factor for developing severe disease. …
Government further expands access to Pfizer's COVID-19 antiviral
March 30, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
Australians with chronic disease call for stronger investment in PBS
October 29, 2025 - - Latest News -
Australia launches first clinical and commercial-scale viral vector manufacturing facility
October 28, 2025 - - Latest News -
Myrio Therapeutics partners with leading US research institutions to advance T cell immunotherapies for solid tumours
October 28, 2025 - - Australian Biotech -
MTPConnect signs cooperation agreement with Saudi Ministry of Health to boost life sciences collaboration
October 28, 2025 - - Australian Biotech -
ObvioHealth partners with Vaxxas to advance needle-free vaccination through digital clinical trials
October 28, 2025 - - Australian Biotech -
AbbVie appoints David Manifold to lead Immunology ANZ and New Zealand operations
October 28, 2025 - - Latest News -
Australians want better access to medical technology, and a clearer pathway to get there
October 28, 2025 -